MARKET

HURA

HURA

TuHURA Biosciences
NASDAQ
2.450
+0.110
+4.70%
After Hours: 2.450 0 0.00% 17:55 07/01 EDT
OPEN
2.340
PREV CLOSE
2.340
HIGH
2.579
LOW
2.315
VOLUME
568.75K
TURNOVER
--
52 WEEK HIGH
3.900
52 WEEK LOW
0.4100
MARKET CAP
156.02M
P/E (TTM)
-4.0349
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HURA last week (0622-0626)?
Weekly Report · 2d ago
Tuhura Biosciences announces annual shareholder meeting webcast
PUBT · 5d ago
Weekly Report: what happened at HURA last week (0615-0619)?
Weekly Report · 06/22 10:33
TuHURA Sets 2026 Virtual Annual Meeting, Proposal Deadlines
TipRanks · 06/17 22:27
Tuhura Biosciences announces 2026 annual shareholder meeting
PUBT · 06/17 20:31
TuHURA Biosciences files IND application with FDA for study of TBS-2025
TipRanks · 06/15 11:53
TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia
Benzinga · 06/15 11:52
TuHURA Biosciences files FDA IND for TBS-2025 VISTA antibody in AML, blood cancers
PUBT · 06/15 11:49
More
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.

Webull offers TuHURA Biosciences Inc stock information, including NASDAQ: HURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HURA stock methods without spending real money on the virtual paper trading platform.